The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global artificial vital organs and medical bionics market size reached US$ 41.3 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 60.67 Billion by 2027, exhibiting a growth rate (CAGR) of 6.50% during 2022-2027.
Artificial vital organs are engineered devices that can be implanted into the human body for replacing a natural organ. They reduce the harmful impact of damaged organs while patients wait for organ transplants. On the other hand, medical bionics is a multidisciplinary field of research for developing implantable devices, which are designed to provide long-term safety and effective sensory or motor function to nerve or muscle tissues. They are used to develop cloned liver cells that filter toxins from the plasma and secrete albumin proteins and clotting factors like a normal liver. They also assist in designing an intravenous membrane oxygenator (IMO), which is integrated directly within the vena cava system to oxygenate the blood as it returns to the heart before reaching the natural lungs.
At present, there is a rise in the prevalence of various diseases, such as respiratory ailments, cirrhosis, and heart, kidney, and liver failures. This, along with the burgeoning healthcare industry, represents one of the key factors driving the market. Besides this, the increasing geriatric population that is highly prone to organ disorders across the globe is contributing to the growth of the market. In addition, the growing development of novel products, such as full-functioning artificial hearts, livers, lungs, urethras, windpipes, and livers, is positively influencing the market. Moreover, key market players are extensively investing in research and development (R&D) activities to introduce new techniques of organ regeneration through engineered tissues, which is offering a positive market outlook. Apart from this, the rising demand for artificial organs due to the development of bioartificial organs with improved survival rates and faster recuperation of patients is propelling the growth of the market. Additionally, the implementation of life-saving technologies, such as the bridge to transplant and the bridge to recovery in critical cases, is bolstering the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial vital organs and medical bionics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type and application.
Breakup by Product Type:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abiomed, BiVACOR Inc, CARMAT, Cirtec Medical, Edwards Lifesciences, Ekso Bionics Holdings Inc., Nikkiso Co. Ltd., Second Sight Medical Products Inc and SynCardia Systems LLC (Picard Medical Inc.).
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abiomed, BiVACOR Inc, CARMAT, Cirtec Medical, Edwards Lifesciences, Ekso Bionics Holdings Inc., Nikkiso Co. Ltd., Second Sight Medical Products Inc and SynCardia Systems LLC (Picard Medical Inc.).|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at